Kimberly Wolf Email and Phone Number
Kimberly Wolf work email
- Valid
- Valid
- Valid
- Valid
- Valid
Kimberly Wolf personal email
- Valid
- Valid
Kimberly Wolf phone numbers
Dynamic, results-focused senior pharmaceutical leader with demonstrated success in biotechnology and traditional pharmaceutical businesses. Strong global and US commercial experience on products with sales ranging from $150M to >$1B. Proven results leading pharmaceutical product/drug development teams Phase II through launch and LCM. Lead and build large teams, develop markets and commercial strategies in a range of therapeutic areas (experience in more than 20 indications, including hematology, oncology and cell therapy); global commercial strategy, product launches, lifecycle planning, and commercial leadership through all stages of product lifecycle. Adept at driving complex organizational transformation via direct and matrix organizations. High EQ, people management/interpersonal and communication skills.Therapeutic experience includes: hematology, oncology, cell therapy, dermatology (psoriasis, atopic dermatitis), rheumatology (psoriatic arthritis, ankylosing spondylitis, Behcet's disease), IBD (ulcerative colitis, Crohn's disease, EOE), virology (hepatitis and HIV), cardiovascular disease and CNS.
Beigene
View-
Svp Global Commercial Strategy And OperationsBeigene Apr 2024 - PresentCambridge, Ma, Us
-
Vice President, Global Hematology, Lung And Precision Medicine Franchise LeadPfizer May 2022 - Apr 2024New York, New York, Us -
Vp, Worldwide Commercial Cell Therapy Franchise Head (Car T)Bristol Myers Squibb Oct 2020 - Nov 2021Lawrence Township, Nj, UsLed the worldwide commercial cell therapy franchise, including creating and implementing global strategy for Breyanzi and Abecma, with US, EU and Japan launches in 2021. Oversaw brand, franchise marketing and operations teams across all indications and markets. -
Vp, Worldwide Lymphoma Commercial StrategyBristol Myers Squibb Jan 2020 - Oct 2020Lawrence Township, Nj, UsJoined BMS’s hematology organization following the $74B acquisition of Celgene in late 2019. Developed disease and asset strategy for lymphoma and CLL across markets and functions, including BD and overall commercial strategy (including patient identification) for molecular diagnostics.
-
Vp Head Of Project Leadership, I&I At CelgeneCelgene 2018 - Jan 2020Summit, New Jersey, UsProvided leadership, direction and decision-making, and drove cross-functional execution of all I&I assets by leading a group of development project leaders and project managers across different therapeutic areas: dermatology, rheumatology, gastroenterology and fibrosis; assets ranged from proof-of-concept through lifecycle management. -
Project LeaderCelgene 2016 - 2018Summit, New Jersey, UsProject Leader for Otezla (rheumatology and dermatology)Project Leader for GED-0301 (Crohn's disease and ulcerative colitis)
-
Head Of Global Otezla Marketing, I&ICelgene 2013 - 2016Summit, New Jersey, UsBuilt and led Global Marketing team for Otezla across six indications and one formulation (PsO, PsA, AS, AD, BCT, UC and QD), in various stages of development from Phase II through global launches in psoriatic arthritis and psoriasis. Led integrated pre-launch/launch activities across psoriatic arthritis and psoriasis through launches in all key markets; Otezla hit >$1 billion sales two years post launch—ahead of all competitor analogs
-
Executive Director, I&I, Cr&DCelgene Jul 2012 - Jun 2013Summit, New Jersey, UsJoined newly formed Inflammation and Immunology business unit within Celgene pre-Phase 3 data to advance infrastructure and communication related to lead compound.
-
Head Of Americas Marketing, Marketing Services And Market Research, Medical DiagnosticsGe Healthcare 2010 - 2012Chicago, UsDirected marketing, marketing services and market research teams for US, Latin American and Canada—spanning nine pharmaceutical (diagnostic) products with $850M combined revenue), across a multiple of therapeutic areas, including cardiovascular, neurology and oncology; major modalities include X-ray, MRI, Ultrasound and Molecular Imaging. -
Commercial Lead Hepatitis B Business UnitBristol-Myers Squibb 2009 - 2010Lawrence Township, Nj, UsUS Commercial Lead for Baraclude Business Unit, #1 antiviral for chronic hepatitis B. Responsible for marketing, sales and advocacy—team of 50, driving commercial strategy and operations across all channels. Managed full P&L.
-
Brand Lead, ReyatazBristol-Myers Squibb 2007 - 2009Lawrence Township, Nj, UsUS Marketing Brand Lead for Reyataz, #1 protease inhibitor utilized in combination with other antiretroviral products--team of 8. Responsible for driving all commercial activities for the brand, including global responsibilities; projected US sales of more than $900 million year-end 2009—double digit growth YOY.
-
Director, Global Marketing, BaracludeBristol-Myers Squibb 2005 - 2007Lawrence Township, Nj, UsGlobal lead for EU pre-launch/launch, Lifecycle Management, Public Relations and Strategic Planning. Aligned strategies with key global brand business opportunities and operationalized key components of EU plan. Corporate marketing coach for competitive and lifecycle planning.
-
Director, Global Marketing, Edifoligide (Cardiovascular)Bristol-Myers Squibb May 2004 - Jan 2005Lawrence Township, Nj, UsGlobal lead for cardiothoracic pre-launch activities for specialty product in Phase III development (product failed Phase III trial) (in conj with JV partner).
-
Associate Director, Global Marketing (Cardiovascular)Bristol-Myers Squibb Aug 2003 - Apr 2004Lawrence Township, Nj, UsDrove commercialization assessment and strategy for Phase II (product failed) and early development thrombosis compounds.
-
Additional ExperiencePharmacia Corporation Jan 2000 - Jun 2003Company acquired by Pfizer in 2003. Earned a series of promotions working across CNS and urology products. -SPM/Associate Director, Detrol LA (overactive bladder)-SPM, CNS Products-Market Manager, CNS
Kimberly Wolf Education Details
-
University Of North Carolina At Chapel HillPublic Health -
Washington And Lee UniversityJournalism
Frequently Asked Questions about Kimberly Wolf
What company does Kimberly Wolf work for?
Kimberly Wolf works for Beigene
What is Kimberly Wolf's role at the current company?
Kimberly Wolf's current role is Global Biotech & Pharmaceutical Executive—Commercial Strategy and Execution and Drug Development.
What is Kimberly Wolf's email address?
Kimberly Wolf's email address is kw****@****ene.com
What is Kimberly Wolf's direct phone number?
Kimberly Wolf's direct phone number is +173265*****
What schools did Kimberly Wolf attend?
Kimberly Wolf attended University Of North Carolina At Chapel Hill, Washington And Lee University.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial